Literature DB >> 21822956

Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas?

Christina Schindera1, Kevin Wingeier, Barbara Goeggel Simonetti, Miriam Diepold, Claude B Nauer, Johannes Fleischhauer, Maja Steinlin.   

Abstract

PURPOSE: Optic pathway gliomas, which occur in 15-20% of paediatric patients with neurofibromatosis type 1, are the most common central nervous system tumour associated with this neurocutaneous disorder. The detection of optic pathway gliomas is essential for further management but is often delayed in infancy due to oligosymptomatic progression and difficulties in clinical detection. Therefore, the aim of our study was to find a clinical indicator for the presence of optic pathway gliomas in children with neurofibromatosis type 1 in order to facilitate early diagnosis and initiate further ophthalmological and neuroimaging investigations.
METHODS: We retrospectively evaluated 70 patients (mean age of 10.5 years; SD of 4.3 years; range of 0.5-19.6 years; 35 females) with neurofibromatosis type 1 seen at the University Children's Hospital of Bern, Switzerland, between January 1998 and December 2008 regarding clinical features of neurofibromatosis type 1 in relation to the presence of optic pathway gliomas.
RESULTS: Fifty-seven of the 70 patients (81.4%) had no clinical or radiological signs of optic pathway gliomas [magnetic resonance imaging (MRI) of the brain in 26/57], whereas 13/70 patients (18.6%) were diagnosed with optic pathway gliomas by MRI. Patients with optic pathway gliomas showed macrocephaly significantly more often compared to patients without optic pathway gliomas (8/13 vs. 9/57, respectively; p = 0.004).
CONCLUSION: Macrocephaly significantly correlates with the incidence of optic pathway gliomas in children with neurofibromatosis type 1. We therefore hypothesise that in otherwise asymptomatic patients, macrocephaly is an additional indicator for performing MRI to detect optic pathway gliomas.

Entities:  

Mesh:

Year:  2011        PMID: 21822956     DOI: 10.1007/s00381-011-1554-2

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  18 in total

1.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

Review 2.  National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.

Authors: 
Journal:  Neurofibromatosis       Date:  1988

3.  The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.

Authors:  Shelley L Hyman; Arthur Shores; Kathryn N North
Journal:  Neurology       Date:  2005-10-11       Impact factor: 9.910

4.  Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

Authors:  N Lau; M M Feldkamp; L Roncari; A H Loehr; P Shannon; D H Gutmann; A Guha
Journal:  J Neuropathol Exp Neurol       Date:  2000-09       Impact factor: 3.685

5.  Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities.

Authors:  R G Steen; J S Taylor; J W Langston; J O Glass; V R Brewer; W E Reddick; R Mages; E K Pivnick
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

6.  Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history.

Authors:  R Listernick; C Darling; M Greenwald; L Strauss; J Charrow
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

7.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain.

Authors:  D P DiPaolo; R A Zimmerman; L B Rorke; E H Zackai; L T Bilaniuk; A T Yachnis
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

8.  Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities.

Authors:  K North; P Joy; D Yuille; N Cocks; E Mobbs; P Hutchins; K McHugh; M de Silva
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

9.  Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia.

Authors:  M J Giordano; D K Mahadeo; Y Y He; R T Geist; C Hsu; D H Gutmann
Journal:  J Neurosci Res       Date:  1996-01-15       Impact factor: 4.164

10.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

View more
  4 in total

1.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

2.  Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.

Authors:  Robert A Avery; Awais Mansoor; Rabia Idrees; Carmelina Trimboli-Heidler; Hiroshi Ishikawa; Roger J Packer; Marius George Linguraru
Journal:  Neurology       Date:  2016-11-04       Impact factor: 9.910

Review 3.  Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.

Authors:  Alessio Ardizzone; Anna Paola Capra; Michela Campolo; Alessia Filippone; Emanuela Esposito; Silvana Briuglia
Journal:  Biomedicines       Date:  2022-04-19

4.  Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.

Authors:  Diogo Lisbôa Basto; Gustavo de Souza Vieira; Raquel M Andrade-Losso; Paula Nascimento Almeida; Vincent M Riccardi; Rafaela Elvira Rozza-de-Menezes; Karin Soares Cunha
Journal:  Orphanet J Rare Dis       Date:  2022-09-05       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.